z-logo
Premium
Imatinib mesylate minimally affects bcr‐abl + and normal monocyte‐derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell‐T cell activation
Author(s) -
Boissel Nicolas,
Rousselot Philippe,
Raffoux Emmanuel,
Cayuela JeanMichel,
Soulier Jean,
Mooney Nuala,
Charron Dominique,
Dombret Hervé,
Toubert Antoine,
Rea Delphine
Publication year - 2006
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.0705419
Subject(s) - imatinib mesylate , dendritic cell , imatinib , biology , monocyte , abl , cancer research , cd86 , breakpoint cluster region , tyrosine kinase , t cell , microbiology and biotechnology , immunology , myeloid leukemia , antigen , signal transduction , immune system , receptor , biochemistry
In chronic myeloid leukemia, bcr‐abl + monocytes provide a unique opportunity to generate dendritic cells (DC) expressing a broad spectrum of leukemic antigens, and bcr‐abl + DC vaccines may allow immunological eradication of leukemic cells persisting under treatment with the tyrosine kinase inhibitor imatinib. However, the efficiency of bcr‐abl + DC vaccines will critically depend on the absence of deleterious effects of bcr‐abl and of imatinib on DC functions. We show that bcr‐abl + monocytes, devoid of contamination of CD14 low granulocytic precursors, differentiate into DC with typical immunophenotypical and functional features, and bcr‐abl transcription decreases simultaneously. During differentiation, imatinib induces a slight increase of DC apoptosis and prevents CD1a up‐regulation in a dose‐dependent manner in bcr‐abl + and normal monocyte‐derived DC, but at most, 25% of DC fail to acquire CD1a. When DC maturation is induced in the presence of imatinib, bcr‐abl + and normal monocyte‐derived DC up‐regulate major histocompatibility complex and costimulatory molecules, CC chemokine receptor 7 and CD83. However, secretion of interleukin‐12p70 is decreased in a dose‐dependent manner. Imatinib exposure of bcr‐abl + and normal monocyte‐derived DC during differentiation and maturation is not detrimental to T cell immunostimulatory functions of DC. In sharp contrast, imatinib, when added to DC‐T cell cultures, profoundly suppresses DC‐mediated T cell proliferation, despite reciprocal DC‐T cell activation attested by up‐regulation of CD25 on T cells and of CD86 on DC. Our findings demonstrate that T cells, not normal or bcr‐abl + monocyte‐derived DC, are major targets for imatinib immunomodulatory effects. It can be envisioned already that imatinib‐free windows will be required to enable vaccination‐induced, leukemia‐specific T cell expansion.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom